Erowid.org: Erowid Reference 752 : Selective reduction of striatal type II glucocorticoid receptors in rats by 3,4-methylenedioxymethamphetamine (MDMA) : Lowy MT, Nash JF Jr, Meltzer HY

Erowid References Database

Lowy MT, Nash JF Jr, Meltzer HY. “Selective reduction of striatal type II glucocorticoid receptors in rats by 3,4-methylenedioxymethamphetamine (MDMA)”. Eur J Pharmacol. 1989;163(1):157-61. <a name="ref">Lowy MT, Nash JF Jr, Meltzer HY.</a> <a href="/references/752">"Selective reduction of striatal type II glucocorticoid receptors in rats by 3,4-methylenedioxymethamphetamine (MDMA)"</a> <i>Eur J Pharmacol</i>. 1989;163(1):157-61.
Text Abstract (this page) Full Text - English (private) Show Articles by Lowy MT Nash JF Jr Meltzer HY Article IDs Erowid RefID: 752 PubMedID: unknown Collections Hofmann Collection MDMA Collection All References	Abstract A single 20 mg/kg dose of 3,4-methylenedioxymethamphetamine (MDMA) administered to rats markedly decreased serotonin (5-HT) and 5-hydroxyindoleacetic acid (5-HIAA) levels in hippocampus, frontal cortex and striatum seven days following injection. MDMA also significantly decreased type II glucocorticoid receptor levels in the striatum, but not in hippocampus or frontal cortex. Since no difference in basal serum corticosterone levels was observed between the two groups, MDMA may decrease striatal type II glucocorticoid receptors via a corticosterone-independent mechanism.
Comments and Responses to this Article #
Submit Comment

[ Cite HTML ]